profit from every $100 of sales.
$0$100
Bristol-Myers Squibb
$62.32-0.94% today
+27.0% in 1 year
1-year low $45.791-year high $68.09
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $18.06 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bristol-Myers Squibb sold, what it kept, and what it did with the cash.
Sales went from $46.2 billion in 2022 to $48.2 billion in 2025, with $7.05 billion of profit last year.
SalesProfit
Bristol-Myers Squibb handed back 39% of the cash it generated last year.
$5.0B
Free cash flow 2025$12.8B
Bought back its own shares$0
Paid as dividends$5.0B
Cash vs. debt$10.2B vs. $47.1B
Bristol-Myers Squibb vs. similar companies
Bristol-Myers Squibb grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bristol-Myers Squibb | 18.1× · Fair price | ||
 Eli Lilly | 61.6× · Very expensive | ||
 Johnson & Johnson | 25.5× · Fair price | ||
 AbbVie | 123.2× · Very expensive | ||
 Roche | 25.7× · Fair price |
Compare Bristol-Myers Squibb with AbbVie · Amgen · Intuitive Surgical · Johnson & Johnson · Eli Lilly · McKesson · Medtronic · Novo Nordisk
AI analysis
An AI analyst reads Bristol-Myers Squibb's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 42,518 | 46,385 | 46,159 | 45,006 | 48,300 | 48,195 | |
| 30,745 | 36,445 | 36,022 | 34,313 | 34,332 | 34,259 | |
| – | – | 9,104 | 8,195 | 5,887 | 13,724 | |
| 4,929 | 20,118 | 19,221 | 19,366 | 3,168 | 15,230 | |
| -9,015 | 6,994 | 6,327 | 8,025 | -8,948 | 7,054 | |
| -3.99 | 3.12 | 2.95 | 3.86 | -4.41 | 3.46 | |
| 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% | |
| – | – | 19.7% | 18.2% | 12.2% | 28.5% | |
| -21.2% | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 118,481 | 109,314 | 96,820 | 95,159 | 92,603 | 90,038 |
| Cash | 14,546 | 13,979 | 9,123 | 11,464 | 10,346 | 10,209 |
| Total debt | 51,673 | 45,596 | 40,717 | 41,464 | 51,200 | 47,139 |
| Total liabilities | 80,599 | 73,308 | 65,702 | 65,674 | 76,215 | 71,532 |
| 37,822 | 35,946 | 31,061 | 29,430 | 16,335 | 18,473 | |
| 2,258 | 2,245 | 2,146 | 2,078 | 2,027 | 2,039 | |
| -4.8% | 9.1% | 9.8% | 10.7% | -7.5% | 13.5% | |
| -23.8% | 19.5% | 20.4% | 27.3% | -54.8% | 38.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 14,052 | 16,207 | 13,066 | 13,860 | 15,190 | 14,156 | |
| 753 | 973 | 1,118 | 1,209 | 1,248 | 1,311 | |
| 13,299 | 15,234 | 11,948 | 12,651 | 13,942 | 12,845 | |
| Dividends paid | 4,075 | 4,396 | 4,634 | 4,744 | 4,863 | 5,045 |
| 1,546 | 6,287 | 8,001 | 5,155 | 0 | 0 | |
| 779 | 583 | 457 | 518 | 507 | 553 |
Valuation
- 18.4×
- 10.1×
- –
- 7.0×
- 2.7×
- 10.1×
- 10.9×
- 9.9%
- 5.4%
- 4.4%
Profitability
- 71.1%
- 28.5%
- 14.6%
- 28.4%
- 13.9%
- 6.8%
- 39.0%
- 8.4%
- 18.5%
- 20.7%
Growth
- +2.5%
- –
- −7.9%
- +1.6%
- −1.7%
Financial health
- 2.4×
- 2.55
- 51.4%
- 5.9×
- 1.26
- 1.28
- 0.56
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 17%of 946
Top 12%of 872
Top 27%of 565
Bottom 21%of 867
Top 7%of 986
What analysts expect
- Average price target
- $62.00
- Range
- $40.00 – $75.00
- 8 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 1.58 | 1.42 | +11.3% |
| Feb 5, 2026 | 1.26 | 1.23 | +2.4% |
| Oct 30, 2025 | 1.63 | 1.52 | +7.2% |
| Jul 31, 2025 | 1.46 | 1.09 | +33.9% |
| Apr 24, 2025 | 1.80 | 1.49 | +20.8% |
| Feb 6, 2025 | 1.67 | 1.47 | +13.6% |
| Oct 31, 2024 | 1.80 | 1.49 | +20.8% |
| Jul 26, 2024 | 2.07 | 1.62 | +27.8% |
4.4%of the share price, paid each year
On $1,000 invested$44a year at today's yield, before tax
+1.6%2020 to 2025
Raised4 yearsin a row, in our data
Paid per share, each year
$1.49 in 2015 → $2.48 in 2025
How safe it looks
71.5% of its profit
Room to growStretchedMore than it earns: 39.3%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
28No pass
Philip Fisher
64Pass
Peter Lynch
33No pass
Joel Greenblatt
42No pass
Charlie Munger
54No pass
Terry Smith
53No pass
Questions about Bristol-Myers Squibb
Is Bristol-Myers Squibb a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bristol-Myers Squibb AI analysis
What does Bristol-Myers Squibb do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. It is in Drug Manufacturers - General, based in Princeton, NJ, United States, with 32,500 employees.
Does Bristol-Myers Squibb pay a dividend?
Yes. At today's price the dividend is 4.4% a year, about 72% of its yearly profit. In 2025 it paid out $5.05 billion in dividends.
Is Bristol-Myers Squibb stock halal?
No. Bristol-Myers Squibb does not pass our halal screen: its debt is 37% of its market value, at or above the 33% limit. How we check
How has Bristol-Myers Squibb stock done over the past year?
Up 27.0% over the past twelve months, to $62.32. It traded between $45.79 and $68.09 and is 8.5% below its high.
Who are Bristol-Myers Squibb's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Bristol-Myers Squibb's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.